Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ILiAD Biotechnologies, LLC

News headline image
ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies to Participate in Upcoming Investor Conferences
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Announces Planned Collaboration with Emmes Group, a New Mountain Capital Portfolio Company, to Conduct Upcoming Phase III Clinical Trials of BPZE1, the Leading Next-Generation Pertussis Vaccine
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Announces Presentation at the 2023 World Vaccine Congress in Barcelona
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Announces Presentation at the World Vaccine Congress
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Announces Publication of BPZE1 Adult Phase 2b Clinical Results in The Lancet
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Announces Presentation of Additional Positive Data for its Next Generation Pertussis Vaccine at the 13th International Bordetella Symposium
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Announces First School-Age Participants Enrolled in BPZE1 Pertussis Vaccine Phase 2b SUPER Clinical Trial
From ILiAD Biotechnologies, LLC
Via Business Wire
News headline image
ILiAD Biotechnologies Reports Preliminary Data Demonstrating Pertussis Vaccine Candidate BPZE1, but Not Boostrix, Induces Functional Bactericidal Antibodies Against Pertactin Negative B. Pertussis
From ILiAD Biotechnologies, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.